KEYTRUDA® (pembrolizumab) as Monotherapy Reduced the Risk of Disease Progression or Death by 43% for Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy
Key Highlights
- ➤KEYTRUDA cut progression or death risk 43% versus platinum doublet chemotherapy
- ➤Median PFS reached 38.2 months with KEYTRUDA versus 8.4 months with chemotherapy
- ➤KEYTRUDA showed favorable overall-survival trend; median OS was not reached
- ➤Grade ≥3 treatment-related adverse events occurred in 18.1% versus 50.7%
- ➤Confirmed response rates were 64.1% with KEYTRUDA versus 62.1% with chemotherapy
Expert Statements
Brian Slomovitz, Director of Gynecologic Oncology and deputy director of the Braman Comprehensive Cancer Center at Mount Sinai Medical Center; study overall principal investigator
“These results highlight the potential of a chemotherapy-free approach for certain patients with dMMR advanced or recurrent endometrial cancer, with pembrolizumab monotherapy demonstrating a clinically meaningful benefit in progression-free survival compared to chemotherapy.”
Brian Slomovitz, Director of Gynecologic Oncology and deputy director of the Braman Comprehensive Cancer Center at Mount Sinai Medical Center; study overall principal investigator
“After years of platinum-based chemotherapy serving as the frontline standard, these findings could help provide an additional treatment option beyond carboplatin plus paclitaxel in combination with KEYTRUDA for these patients.”
Gursel Aktan, Vice president, global clinical development, Merck Research Laboratories
“KEYTRUDA is already part of an established treatment regimen with platinum doublet chemotherapy for patients with primary advanced or recurrent endometrial cancer regardless of mismatch repair status, and we’re excited by these results showing its further potential as a monotherapy option for appropriate patients whose tumors are dMMR.”
Gursel Aktan, Vice president, global clinical development, Merck Research Laboratories
“As incidence rates of endometrial cancer continue to rise, we remain committed to advancing new potential treatment options for women facing this disease.”
KEYTRUDA(®) (pembrolizumab) as Monotherapy Reduced the Risk of Disease Progression or Death by 43% for Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy
KEYNOTE-C93 showed median progression-free survival (PFS) was more than four times longer for these patients treated with KEYTRUDA as monotherapy (38.2 months) compared to platinum doublet chemotherapy (8.4 months)
Get started
Create a free account to read the full story.